<DOC>
	<DOCNO>NCT00125996</DOCNO>
	<brief_summary>This two-center , randomise , single-blind ( physician ) , prospective , control study ass acute ( 8 week ) chronic ( 16 week ) effect intravenous ( IV ) iron sucrose supplementation anaemic non-anaemic iron deficient patient chronic heart failure ( CHF ) . The hypothesis : - Treatment anaemic non-anaemic iron-deficient CHF patient IV iron sucrose improve exercise capacity measure peak VO2 . - IV iron sucrose safe well tolerated subject moderate severe CHF .</brief_summary>
	<brief_title>Effect Intravenous Ferrous Sucrose Exercise Capacity Chronic Heart Failure</brief_title>
	<detailed_description>Study Phase Design : Prospective two-centre , randomize , control , open-label , observer-blinded , parallel-group study Primary Objective : To evaluate effect intravenous ( IV ) iron supplementation exercise tolerance , determine peak VO2 . Secondary Objectives : - To evaluate effect IV iron supplementation exercise duration , leave ventricular ( LV ) structure function , symptom status ( NYHA class , Minnesota Living Heart Failure Questionnaire [ MLHFQ ] , subjective fatigue score ) , haematological biochemical ( haemoglobin [ Hb ] , haematocrit [ Hct ] , iron status , N-BNP , cytokine oxidative stress ) index . - To evaluate safety profile IV iron subject moderate severe CHF . Sample Size : 42 subject ( 28 IV iron , 14 placebo ) ; 50 % anaemic 50 % non-anaemic</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<criteria>≥21 year age sign write informed consent Stable symptomatic CHF ; NYHA III/IV leave ventricular ejection fraction ( LVEF ) ≤40 % , NYHA II LVEF must ≤35 % , assess within last 6 month use echocardiographic magnetic resonance image technique . On optimal conventional therapy least 4 week prior recruitment without dose change least 2 week . Peak VO2 ≤ 18 ml/kg/min modify Naughton protocol cardiopulmonary exercise testing . Mean 2 screen Hb concentration ( week2 week1 ) &lt; 12.5 g/dl ( anaemic group , 50 % study population ) 12.514.0 g/dl ( nonanaemic group , 50 % study population ) . Ferritin &lt; 100 µg/l 100300 µg/l TSAT &lt; 20 % . Normal red cell folate vitamin B12 status ( accord local lab reference range ) . Resting blood pressure ≤160/100 mmHg . History acquire iron overload ; know haemochromatosis first relatives haemochromatosis ; allergic disorder ( asthma , eczema , anaphylactic reaction ) . Known hypersensitivity parental iron preparation . Known active infection , bleeding , malignancy haemolytic anaemia . History chronic liver disease and/or alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 3 time upper limit normal range ; chronic lung disease ; myelodysplastic disorder ; know HIV/AIDS disease . Recipient immunosuppressive therapy renal dialysis . History erythropoietin , IV oral iron therapy , blood transfusion previous 30 day . Unstable angina pectoris , judge investigator ; severe uncorrected valvular disease leave ventricular outflow obstruction ; obstructive cardiomyopathy ; uncontrolled fast atrial fibrillation flutter ( heart rate &gt; 110 beat per minute [ bpm ] ) ; uncontrolled symptomatic brady tachyarrhythmias . Musculoskeletal limitation , judgement investigator , would impair cardiopulmonary exercise test . Pregnant breastfeed Inability comprehend study protocol Parallel participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>ANAEMIA</keyword>
	<keyword>Iron Deficiency</keyword>
</DOC>